Abstract
Venous thromboembolism (VTE) is the third cause of morbidity and mortality in western countries with an incidence rate of 1–3 per 1000 individuals/year [1]. In recent years, new direct oral anticoagulants (DOAC) have been developed, including factor IIa and FXa inhibitors, and a number of randomized controlled trials (RCTs) in patients with acute VTE showed a comparable efficacy and a superior safety of DOAC compared to vitamin K antagonist (VKA) [2,3]. Moreover, data of two recent meta-analyses have further confirmed that these compounds are at least as effective in reducing the VTE recurrences compared to VKAs [4,5].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
